Reporting suspected adverse reactions to new commercialized medicines in real world

Abstract

Keywords

Alemtuzumab autoimmune haemolytic anaemia

Get full access to this article

View all access options for this article.

References

Havrdova

Horakova

Kovarova

Alemtuzumab in the treatment of multiple sclerosis: Key clinical trial results and considerations for use. Ther Adv Neurol Disord 2015; 8: 31–45.

Costelloe

Jones

Coles

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev Neurother 2012; 12: 335–341.

Coles

Twyman

Arnold

et al . Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet 2012; 380: 1829–1839.

Cohen

Coles

Arnold

et al . Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012; 380: 1819–1828.

Brown

Coles

AJ.

Alemtuzumab: Evidence for its potential in relapsing-remitting multiple sclerosis. Drug Des Devel Ther 2013; 7: 131–138.